The charts on this page feature a breakdown of the total annual pay for the top executives at AKCEA THERAPEUTICS, INC. as reported in their proxy statements.

Total Cash Compensation information is comprised of yearly Base Pay and Bonuses. AKCEA THERAPEUTICS, INC. income statements for executive base pay and bonus are filed yearly with the SEC in the edgar filing system. AKCEA THERAPEUTICS, INC. annual reports of executive compensation and pay are most commonly found in the Def 14a documents.

Total Equity aggregates grant date fair value of stock and option awards and long term incentives granted during the fiscal year.

Other Compensation covers all compensation-like awards that don't fit in any of these other standard categories. Numbers reported do not include change in pension value and non-qualified deferred compensation earnings.

Name And Title Total Cash Equity Other Total Compensation
Paula Soteropoulos
Former Chief Executive Officer
Total Cash $420,270 Equity $6,153,759 Other $827,979 Total Compensation $7,402,008
Damien McDevitt
Interim Chief Executive Officer
Total Cash $246,335 Equity $10,304,650 Other $10,464 Total Compensation $10,561,449
Sarah Boyce
Former President
Total Cash $385,318 Equity $3,596,624 Other $535,427 Total Compensation $4,517,369
Alex G. Howarth
Chief Operating Officer
Total Cash $84,615 Equity $4,400,387 Other $25,603 Total Compensation $4,510,605
Kyle Jenne
Chief Commercial Officer
Total Cash $522,272 Equity $3,042,281 Other $22,345 Total Compensation $3,586,898
For its 2018 fiscal year, AKCEA THERAPEUTICS, INC., listed the following board members on its annual proxy statement to the SEC.
B. Lynne Parshall Total Cash $1,514,097
Christopher Gabrieli Total Cash $563,579
Edward Fitzgerald Total Cash $590,579
Elaine Hochberg Total Cash $533,579
Richard A. Moscicki Total Cash $1,492,886
Sandford D. Smith Total Cash $592,579

This report is not for commercial use. Thorough reviews have been conducted to assure this data accurately reflects disclosures. However for a complete and definitive understanding of the pay practices of any company, users should refer directly to the actual, complete proxy statement.

The information shown here is a reporting of information included in the company's proxy statement. The proxy statement includes footnotes and explanations of this information plus other information that is pertinent in assessing the overall value and appropriateness of the compensation information. For those interested in conducting a detailed compensation analysis, we recommend that you review the entire proxy statement. You may retrieve the full proxy statement by going to the Securities and Exchange Commission (SEC) website at and entering the company's name and then looking in the first column for an entry of "Form DEF 14A" (or any similar code). You may also find the annual proxy statement by going directly to the company's website.

A proxy statement (or "proxy") is a form that every publicly traded U.S. company is required to file with the U.S. Securities & Exchange Commission (SEC) within 120 days after the end of its fiscal year. The proxy must be sent to every shareholder in advance of the company's annual shareholders meeting. All proxy statements are public filings made available to the general public by the SEC.

The proxy statement's main purpose is to alert shareholders to the annual meeting and provide them information about the issues that will be voted on during the annual meeting, including decisions such as electing directors, ratifying the selection of auditors, and other shareholder-related decisions, including shareholder-initiated initiatives. Also, proxies must disclose specific detailed information regarding the pay practices for certain executives.